American College of Gastroenterology Annual Meeting

American College of Gastroenterology Annual Meeting

Source:

Dubinksy M, et al. Abstract: Efficacy and safety of risankizumab as maintenance therapy in patients with Crohn's disease: 52-week results from the phase 3 FORTIFY study. Presented at: ACG Annual Scientific Meeting; Oct. 22-27, 2021. Las Vegas (hybrid meeting).

Disclosures: Dubinsky reports consulting for AbbVie, Arena, Bristol Myers Squibb, Celgene, Genentech, Janssen, Pfizer, Prometheus Labs and Takeda.
November 03, 2021
1 min watch
Save

VIDEO: Skyrizi induces clinical remission, endoscopic response in Crohn’s

Source:

Dubinksy M, et al. Abstract: Efficacy and safety of risankizumab as maintenance therapy in patients with Crohn's disease: 52-week results from the phase 3 FORTIFY study. Presented at: ACG Annual Scientific Meeting; Oct. 22-27, 2021. Las Vegas (hybrid meeting).

Disclosures: Dubinsky reports consulting for AbbVie, Arena, Bristol Myers Squibb, Celgene, Genentech, Janssen, Pfizer, Prometheus Labs and Takeda.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

LAS VEGAS – Patients dosed with Skyrizi for Crohn’s disease achieved clinical remission, endoscopic response and persistent improvements to inflammatory biomarkers consistent with a dose-response relationship.

“This was exciting to finally see the 52-week induction study for risankizumab [Skyrizi, AbbVie] for Crohn's disease,” Marla Dubinsky, MD, of the Icahn School of Medicine, said in a Healio Gastroenterology video exclusive. “We hope to look for approval sometime in 2022.”